The hierarchy of evidence: From unsystematic clinical observations to systematic reviews

Neurology: An Evidence-Based Approach

Volumn , Issue , 2012, Pages 11-24

  Elamin, Mohamed B ^a   Montori, Victor M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Evidence based medicine; Hierarchy of evidence; Study design

Indexed keywords

EID: 84879367820     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-88555-1_2     Document Type: Chapter

References (28)

1. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users’ Guides to the Medical Literature: XXV. Evidence-based medicine: principles for applying the Users’ Guides to patient care. Evidence-Based Medicine Working Group. JAMA. 2000;284(10):1290–6.
2. Guyatt G, Rennie D, Meade MO, Cook DJ. User’s guide to the medical literature: a manual for evidence-based clinical practice. 2nd ed. London: AMA; 2002.
3. Delcourt R, Vastesaeger M. Action of atromid on total and beta-cholesterol. J Atheroscler Res. 1963;3:533–7.
4. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J. 1978;40(10):1069–118.
5. de Bittencourt PR, Gomes-da-Silva MM. Multiple sclerosis: long-term remission after a high dose of cyclophosphamide. Acta Neurol Scand. 2005;111(3):195–8.
6. Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol. 1999;99(1):142–9.
7. Marrie RA, Wolfson C, Sturkenboom MC, et al. Multiple sclerosis and antecedent infections: a case-control study. Neurology. 2000;54(12):2307–10.
8. Putzki N, Katsarava Z, Vago S, Diener HC, Limmroth V. Prevalence and severity of multiplesclerosis-associated fatigue in treated and untreated patients. Eur Neurol. 2008;59(3–4): 136–42.
9. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.
10. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–86.
11. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet. 1999;353(9171):2179–84.
12. Hankey GJ, Todd AA, Yap PL, Warlow CP. An “n of 1” trial of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1994;57(9):1137.
13. Popp AJ, Chater N. Extracranial to intracranial vascular anastomosis for occlusive cerebrovascular disease: experience in 110 patients. Surgery. 1977;82(5):648–54.
14. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group. N Engl J Med. 1985;313(19):1191–200.
15. Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001;165(10):1339–41.
16. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet. 1991;337(8739): 441–6.
17. La Mantia L, Milanese C, Mascoli N, D’Amico R, Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev. 2007(1):CD002819.
18. Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care. 1986;2(1):53–63.
19. Campbell SM, Braspenning J, Hutchinson A, Marshall M. Research methods used in developing and applying quality indicators in primary care. Qual Saf Health Care. 2002;11(4):358–64.
20. The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1979;121(9):1193–254.
21. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38.
22. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21–35.
23. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol. 1990;43(9):891–905.
24. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989;95(2 Suppl):2S-4.
25. Guyatt G, Schunemann H, Cook D, Jaeschke R, Pauker S, Bucher H. Grades of recommendation for antithrombotic agents. Chest. 2001;119(1 Suppl):3S-7.
26. Oxford Centre for Evidence-based Medicine Levels of Evidence. http://www.cebm.net/index.aspx?o=1025. Accessed Feb 2009.
27. Edlund W, Gronseth G, So Y, Franklin G. Clinical practice guideline process manual, 2004 Edition, Appendix 9. The American Academy of Neurology. http://www.aan.com/globals/axon/assets/3749.pdf. Accessed Feb 2009.
28. Guyatt G. Evidence-based medicine. ACP J Club (Ann Intern Med). 1991;114(Suppl 2):A-16.